Multiple sclerosis involves demyelination and axonal degeneration of the central nervous system. The molecular mechanisms of axonal degeneration are relatively unexplored in both multiple sclerosis and its mouse model, experimental autoimmune encephalomyelitis. We previously reported that targeting the axonal growth inhibitor, Nogo-A, may protect against neurodegeneration in experimental autoimmune encephalomyelitis; however, the mechanism by which this occurs is unclear. We now show that the collapsin response mediator protein 2 (CRMP-2), an important tubulin-associated protein that regulates axonal growth, is phosphorylated and hence inhibited during the progression of experimental autoimmune encephalomyelitis in degenerating axons. The phosphorylated form of CRMP-2 (pThr555CRMP-2) is localized to spinal cord neurons and axons in chronic-active multiple sclerosis lesions. Specifically, pThr555CRMP-2 is implicated to be Nogo-66 receptor 1 (NgR1)-dependent, since myelin oligodendrocyte glycoprotein (MOG)35–55-induced NgR1 knock-out (ngr1−/−) mice display a reduced experimental autoimmune encephalomyelitis disease progression, without a deregulation of ngr1−/− MOG35–55-reactive lymphocytes and monocytes. The limitation of axonal degeneration/loss in experimental autoimmune encephalomyelitis-induced ngr1−/− mice is associated with lower levels of pThr555CRMP-2 in the spinal cord and optic nerve during experimental autoimmune encephalomyelitis. Furthermore, transduction of retinal ganglion cells with an adeno-associated viral vector encoding a site-specific mutant T555ACRMP-2 construct, limits optic nerve axonal degeneration occurring at peak stage of experimental autoimmune encephalomyelitis. Therapeutic administration of the anti-Nogo(623–640) antibody during the course of experimental autoimmune encephalomyelitis, associated with an improved clinical outcome, is demonstrated to abrogate the protein levels of pThr555CRMP-2 in the spinal cord and improve pathological outcome. We conclude that phosphorylation of CRMP-2 may be downstream of NgR1 activation and play a role in axonal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Blockade of Nogo-A/NgR1 interaction may serve as a viable therapeutic target in multiple sclerosis.
Accumulation of the amyloid protein (Aβ) in the brain is an important step in the pathogenesis of Alzheimer’s disease. However, the mechanism by which Aβ exerts its neurotoxic effect is largely unknown. It has been suggested that the peptide can bind to the α7 nicotinic acetylcholine receptor (α7nAChR). In this study, we examined the binding of Aβ1‐42 to endogenous and recombinantly expressed α7nAChRs. Aβ1‐42 did neither inhibit the specific binding of α7nAChR ligands to rat brain homogenate or slice preparations, nor did it influence the activity of α7nAChRs expressed in Xenopus oocytes. Similarly, Aβ1‐42 did not compete for α‐bungarotoxin‐binding sites on SH‐SY5Y cells stably expressing α7nAChRs. The effect of the Aβ1‐42 on tau phosphorylation was also examined. Although Aβ1‐42 altered tau phosphorylation in α7nAChR‐transfected SH‐SY5Y cells, the effect of the peptide was unrelated to α7nAChR expression or activity. Binding studies using surface plasmon resonance indicated that the majority of the Aβ bound to membrane lipid, rather than to a protein component. Fluorescence anisotropy experiments indicated that Aβ may disrupt membrane lipid structure or fluidity. We conclude that the effects of Aβ are unlikely to be mediated by direct binding to the α7nAChR. Instead, we speculate that Aβ may exert its effects by altering the packing of lipids within the plasma membrane, which could, in turn, influence the function of a variety of receptors and channels on the cell surface.